Chemohormonal therapy in metastatic hormone-sensitive prostate cancer

New England Journal of Medicine

Volumn 373, Issue 8, 2015, Pages 737-746

  Sweeney, Christopher J ^a,b,c   Chen, Yu Hui ^a   Carducci, Michael ^d   Liu, Glenn ^e   Jarrard, David F ^e,f   Eisenberger, Mario ^d   Wong, Yu Ning ^g   Hahn, Noah ^h   Kohli, Manish ⁱ   Cooney, Matthew M ^j   Dreicer, Robert ^l   Vogelzang, Nicholas J ^m   Picus, Joel ⁿ   Shevrin, Daniel ^o   Hussain, Maha ^p   Garcia, Jorge A ^k   DiPaola, Robert S ^q  

^a Department of Medicine ^*  (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF WISCONSIN   (United States)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^g TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

^h INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ MAYO CLINIC   (United States)

^j UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^k LERNER RESEARCH INSTITUTE   (United States)

^l UNIVERSITY OF VIRGINIA   (United States)

^m Department of Hematology Oncology   (United States)

ⁿ MO   (United States)

^o NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^p UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^q RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CALCIUM CARBONATE; DEXAMETHASONE; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; VITAMIN D; ANTIANDROGEN; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FOLLOW UP; HORMONE SENSITIVITY; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG COMBINATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROSTATIC NEOPLASMS;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEUTROPENIA; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 84939864061     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1503747     Document Type: Article

References (26)

1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7.
2. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Lancet 2000; 355: 1491-8.
3. Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002; 95: 361-76.
4. Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368: 1314-25.
5. Tangen CM, Hussain MH, Higano CS, et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: A SWOG phase III trial experience (S8494, S8894 and S9346). J Urol 2012; 188: 1164-9.
6. Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 2014; 120: 818-23.
7. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20.
8. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.
9. Millikan RE, Wen S, Pagliaro LC, et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 2008; 26: 5936-42.
10. Gravis G, Fizazi K, Joly F, et al. Androgen- deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14: 149-58.
11. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-24.
12. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-42.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
14. Jennison CTB. Statistical approaches to interim monitoring of medical trials: A review and commentary. Stat Sci 1990; 5: 299-317.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
16. Cox DR. Regression models and lifetables. J R Stat Soc B 1972; 34: 187-220.
17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-70.
18. Cox D. Analysis of binary data. London: Methuen and Co., 1970.
19. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
20. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138-48.
21. Beer TM, strong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424-33.
22. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-97.
23. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22.
24. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised openlabel trial. Lancet 2010; 376: 1147-54.
25. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-23.
26. James ND, Spears MR, Clarke NW, et al. Survival with newly diagnosed metastatic prostate cancer in the "docetaxel era": Data from 917 patients in the control of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol 2015; 67: 1028-38.